Document is current
Any future updates will be listed below
-
Authors
Geskin, Larisa
Querfeld, Christiane
Hodak, Emmilia
Nikbakht, Neda
Papadavid, Evangelia
Ardigò, Marco
Wehkamp, Ulrike
Bagot, Martine
-
Funding
Funding for this research was provided by:
Helsinn
- License Information
-
More Information
Article History
Received: 18 September 2024
Accepted: 28 October 2024
First Online: 27 November 2024
Declarations
:
: Larisa Geskin: Consulting fees, payment or honoraria, and/or research grant support: Helsinn, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Recordati Rare Diseases, Regeneron, Sanofi, Merck and Soligenix, UpToDate, and Medscape; patent on method to diagnose cutaneous lymphoma; leadership role: International Society for Cutaneous Lymphomas and United States Cutaneous Lymphoma Consortium; stock/stock options: CelSyntec, Inc. Neda Nikbakht: Advisory board: Helsinn and Kyowa Kirin. Christiane Querfeld: Steering Committee/Advisory Board: Helsinn, Kyowa Kirin; Investigator: Helsinn, Celgene (Bristol Myers Squibb), Kyowa Kirin; Research Grants: Celgene, Helsinn. Emmilia Hodak: Scientific advisory board: Actelion, Helsinn, Recordati Rare Diseases, Takeda, Vidac; speakers’ bureau: Helsinn, Rafa, Takeda. Evangelia Papadavid: Lecturer: Helsinn, Mallinckrodt, AbbVie, Janssen, Novartis. Marco Ardigò: Lecturer: Helsinn, Kyowa Kirin, Takeda, VivaScope, Almirall, Recordati Rare Diseases. Ulrike Wehkamp: Clinical investigator: miRagen, Kyowa Kirin, Innate Pharma, 4SC. Honoraria for lectures/advisory boards: Helsinn, Kyowa Kirin, MSD, Takeda, Mundipharma, Galderma, Stemline. Martine Bagot: Advisory board: Helsinn-Recordati, Kyowa Kirin, Takeda, Innate Pharma.
: This manuscript does not contain any new studies with human participants or animals performed by any of the authors.
